Literature DB >> 8472158

Gastric cancer and Helicobacter pylori infection.

F Buruk1, U Berberoglu, I Pak, E Aksaz, O Celen.   

Abstract

Gastric adenocarcinoma can be divided into two histopathological types: intestinal and diffuse. In addition to the role of environmental factors, an association between gastric cancer and Helicobacter pylori has been suggested. A retrospective study was therefore carried out among 46 patients who had gastric cancer. As a control group, 40 patients with non-malignant disorders were selected (11 patients with peptic ulcer, 12 with chronic superficial gastritis, 17 with chronic atrophic gastritis). Twenty-six cancers were classified as intestinal type and 20 as diffuse type. H. pylori was found in 23 (88 per cent) of the intestinal type and 11 (55 per cent) of the diffuse type (P < 0.05). Patients with the intestinal-type gastric cancer had a higher prevalence of H. pylori infection than those with gastric ulcer (55 per cent) and chronic superficial gastritis (50 per cent) (P < 0.05). These findings suggest that there is a possible association between the intestinal type of gastric cancer and H. pylori infection.

Entities:  

Mesh:

Year:  1993        PMID: 8472158     DOI: 10.1002/bjs.1800800339

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  9 in total

Review 1.  Diet, H pylori infection and gastric cancer: evidence and controversies.

Authors:  Alba Rocco; Gerardo Nardone
Journal:  World J Gastroenterol       Date:  2007-06-07       Impact factor: 5.742

2.  Asymptomatic Helicobacter pylori gastritis is associated with increased sucrose permeability.

Authors:  K Borch; C Sjöstedt; U Hannestad; J D Söderholm; L Franzén; S Mårdh
Journal:  Dig Dis Sci       Date:  1998-04       Impact factor: 3.199

3.  Helicobacter pylori and mucosal atrophy in patients with gastric cancer: a special study regarding the methods for detecting Helicobacter pylori.

Authors:  H Tabata; T Fuchigami; H Kobayashi; Y Sakai; M Nakanishi; K Tomioka; S Nakamura; M Fujishima
Journal:  Dig Dis Sci       Date:  1999-10       Impact factor: 3.199

4.  Helicobacter pylori infection in patients with early gastric cancer by the endoscopic phenol red test.

Authors:  K Iseki; M Tatsuta; H Iishi; M Baba; S Ishiguro
Journal:  Gut       Date:  1998-01       Impact factor: 23.059

5.  Does eradication of Helicobacter pylori reduce the risk of carcinogenesis in the residual stomach after gastrectomy for early gastric cancer? Comparison of mucosal lesions in the residual stomach before and after Helicobacter pylori eradication.

Authors:  K Hamaguchi; K Ogawa; T Katsube; S Konno; M Aiba
Journal:  Langenbecks Arch Surg       Date:  2004-02-06       Impact factor: 3.445

6.  H pylori (CagA) and Epstein-Barr virus infection in gastric carcinomas: correlation with p53 mutation and c-Myc, Bcl-2 and Bax expression.

Authors:  Valeska Portela Lima; Marcos Antonio Pereira de Lima; Angela Rosa André; Márcia Valéria Pitombeira Ferreira; Marcos Aurélio Pessoa Barros; Sílvia Helena Barem Rabenhorst
Journal:  World J Gastroenterol       Date:  2008-02-14       Impact factor: 5.742

7.  Helicobacter pylori associated with a high prevalence of duodenal ulcer disease and a low prevalence of gastric cancer in a developing nation.

Authors:  P J Hu; Y Y Li; M H Zhou; M H Chen; G G Du; B J Huang; H M Mitchell; S L Hazell
Journal:  Gut       Date:  1995-02       Impact factor: 23.059

8.  Rapidly declining trend of signet ring cell cancer of the stomach may parallel the infection rate of Helicobacter pylori.

Authors:  Hiroshi Ohyama; Dai Yoshimura; Yosuke Hirotsu; Kenji Amemiya; Hiroyuki Amano; Yuko Miura; Hiroshi Ashizawa; Keiko Nakagomi; Shinya Takaoka; Kenji Hosoda; Yoji Suzuki; Toshio Oyama; Masao Hada; Yuichiro Kojima; Hitoshi Mochizuki; Masao Omata
Journal:  BMC Gastroenterol       Date:  2019-11-08       Impact factor: 3.067

Review 9.  Time to Classify Tumours of the Stomach and the Kidneys According to Cell of Origin.

Authors:  Helge Waldum; Patricia Mjønes
Journal:  Int J Mol Sci       Date:  2021-12-13       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.